Literature DB >> 10775326

Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry.

K A Regal1, M L Schrag, U M Kent, L C Wienkers, P F Hollenberg.   

Abstract

7-Ethynylcoumarin was synthesized as a potential mechanism-based inhibitor, and it was found to be an effective inactivator of 7-ethoxy-4-(trifluoromethyl)coumarin (7EFC) O-deethylation catalyzed by purified, reconstituted P450 2B1. In contrast, 7-ethynylcoumarin demonstrated minimal inactivation of P450 2A6-mediated 7-hydroxycoumarin formation. The inactivation of P450 2B1 demonstrated pseudo-first-order kinetics and was NADPH- and inhibitor-dependent. The maximal rate constant for the inactivation of 2B1 was 0.39 min(-)(1) at 30 degrees C, and thus, the time required to inactivate 50% of the P450 2B1 that was present (t(1/2)) was 1.8 min. The estimated concentration which led to half-maximal inactivation (K(I)) was 25 microM. No protection from inactivation was seen in the presence of nucleophiles (glutathione and sodium cyanide), an iron chelator (deferroxamine), or superoxide dismutase and catalase. Addition of the substrate (7EFC) protected P450 2B1 from inactivation, in a concentration-dependent manner. The partition ratio for P450 2B1 was 25; i.e., the number of metabolic events was 25-fold higher than the number of inactivating events. Incubations of 7-ethynylcoumarin with P450 2B1 for 10 min resulted in an 80% loss in enzymatic activity, while 90% of the ability to form a reduced-CO complex remained. This activity loss was not recovered following dialysis, indicative of irreversible inactivation. Covalent attachment of the entire inhibitor and oxygen to apo-P450 2B1, in a 1:1 ratio, was shown via electrospray ion trap mass spectrometry. This method also verified the absence of modification to the heme or the cytochrome P450 reductase. Taken together, the characterization of the inhibition seen with P450 2B1 and 7-ethynylcoumarin was consistent with all of the criteria required to distinguish a mechanism-based inactivator. In addition, electrospray ion trap mass spectrometry has the potential to be applied to protein adducts above and beyond those associated with the mechanism-based inactivation of cytochrome P450s.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775326     DOI: 10.1021/tx990195s

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  8 in total

1.  Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity.

Authors:  Sean C Gay; Haoming Zhang; P Ross Wilderman; Arthur G Roberts; Tong Liu; Sheng Li; Hsia-Lien Lin; Qinghai Zhang; Virgil L Woods; C David Stout; Paul F Hollenberg; James R Halpert
Journal:  Biochemistry       Date:  2011-05-13       Impact factor: 3.162

2.  7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2.

Authors:  Jiawang Liu; Thong T Nguyen; Patrick S Dupart; Jayalakshmi Sridhar; Xiaoyi Zhang; Naijue Zhu; Cheryl L Klein Stevens; Maryam Foroozesh
Journal:  Chem Res Toxicol       Date:  2012-04-10       Impact factor: 3.739

Review 3.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

4.  Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds.

Authors:  Amanda K Bolles; Rina Fujiwara; Erran D Briggs; Amin A Nomeir; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2014-10-01       Impact factor: 3.922

5.  Chemical inactivation of the cinnamate 4-hydroxylase allows for the accumulation of salicylic acid in elicited cells.

Authors:  Guillaume A Schoch; Georgi N Nikov; William L Alworth; Danièle Werck-Reichhart
Journal:  Plant Physiol       Date:  2002-10       Impact factor: 8.340

6.  Cysteine 98 in CYP3A4 contributes to conformational integrity required for P450 interaction with CYP reductase.

Authors:  Bo Wen; Jed N Lampe; Arthur G Roberts; William M Atkins; A David Rodrigues; Sidney D Nelson
Journal:  Arch Biochem Biophys       Date:  2006-08-22       Impact factor: 4.013

7.  Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Authors:  Ute M Kent; Hsia-Lien Lin; Danielle E Mills; Kelly A Regal; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

8.  A suite of activity-based probes for human cytochrome P450 enzymes.

Authors:  Aaron T Wright; Joongyu D Song; Benjamin F Cravatt
Journal:  J Am Chem Soc       Date:  2009-08-05       Impact factor: 15.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.